Compare HNVR & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | SPRO |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 156.3M |
| IPO Year | 2022 | 2017 |
| Metric | HNVR | SPRO |
|---|---|---|
| Price | $25.04 | $1.22 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $24.50 | N/A |
| AVG Volume (30 Days) | 54.4K | ★ 1.5M |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | $35.49 | N/A |
| Revenue Next Year | $8.61 | $300.00 |
| P/E Ratio | $99.16 | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $19.91 | $1.10 |
| 52 Week High | $25.61 | $3.08 |
| Indicator | HNVR | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 62.24 | 18.94 |
| Support Level | $22.09 | N/A |
| Resistance Level | $25.61 | $2.44 |
| Average True Range (ATR) | 0.68 | 0.16 |
| MACD | 0.08 | -0.07 |
| Stochastic Oscillator | 75.82 | 6.19 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.